{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:13:51Z","timestamp":1791627231451,"version":"4.3.4"},"reference-count":117,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.chom.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:59:49Z","timestamp":1783522789000},"page":"1285-1301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Breaking down barriers to improve phage therapy delivery"],"prefix":"10.1016","volume":"34","author":[{"given":"Tiffany","family":"Luong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Rybicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"D\u0105browska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-9448","authenticated-orcid":false,"given":"Paul L.","family":"Bollyky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2026.06.013_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01056","article-title":"Phage Therapy in Poland \u2013 a Centennial Journey to the First Ethically Approved Treatment Facility in Europe","volume":"11","author":"\u017baczek","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib2","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.chom.2026.06.013_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-69247-w","article-title":"Ecological partitioning enables phage\u2013antibiotic cooperation in a human Pseudomonas infection","volume":"17","author":"Luong","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01728-23","article-title":"Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases","volume":"68","author":"Aslam","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the Use of Phage Therapy in Clinical Practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.chom.2026.06.013_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI187996","article-title":"Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.chom.2026.06.013_bib11","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt1193","article-title":"Transdermal protein delivery by a coadministered peptide identified via phage display","volume":"24","author":"Chen","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chom.2026.06.013_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg4015","article-title":"The phageome in normal and inflamed human skin","volume":"9","author":"Wielscher","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chom.2026.06.013_bib14","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","article-title":"Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy","volume":"49","author":"Bruttin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106007","article-title":"Bacteriophages playing nice: Lysogenic bacteriophage replication stable in the human gut microbiota","volume":"26","author":"Sutcliffe","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.chom.2026.06.013_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41564-025-02207-0","article-title":"Persistent virulent phages exist across bacterial isolates","volume":"11","author":"Dougherty","year":"2026","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib17","doi-asserted-by":"crossref","first-page":"e01874-17","DOI":"10.1128\/mBio.01874-17","article-title":"Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers","volume":"8","author":"Nguyen","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.chom.2026.06.013_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002341","article-title":"Mammalian cells internalize bacteriophages and use them as a resource to enhance cellular growth and survival","volume":"21","author":"Bichet","year":"2023","journal-title":"PLOS Biol."},{"key":"10.1016\/j.chom.2026.06.013_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02607","article-title":"Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered per os","volume":"10","author":"Majewska","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chom.2026.06.013_bib20","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","author":"D\u0105browska","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.chom.2026.06.013_bib21","article-title":"Phageome transfer from gut to circulation and its regulation by human immunity","author":"Szymczak","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.chom.2026.06.013_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01506-25","article-title":"Whole-body distribution of three Pseudomonas phages characterized by a translational physiologically based pharmacokinetic model","volume":"70","author":"Echterhof","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01359-23","article-title":"Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions","volume":"98","author":"Tan","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.chom.2026.06.013_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002566","article-title":"Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells","volume":"22","author":"Zamora","year":"2024","journal-title":"PLOS Biol."},{"key":"10.1016\/j.chom.2026.06.013_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113513","article-title":"Transcriptomic analysis of phage-mammalian cell interaction reveals diverse phage immunobarcodes","volume":"28","author":"Muema","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.chom.2026.06.013_bib26","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1073\/pnas.93.8.3188","article-title":"Long-circulating bacteriophage as antibacterial agents","volume":"93","author":"Merril","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chom.2026.06.013_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep14802","article-title":"Mammalian Host-Versus-Phage immune response determines phage fate in vivo","volume":"5","author":"Hodyra-Stefaniak","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2026.06.013_bib28","first-page":"173","article-title":"The actvity of mouse Kupffer cells following intravenous injection of T4 bacteriophage","volume":"5","author":"Inchley","year":"1969","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.chom.2026.06.013_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181309","article-title":"The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo","volume":"9","author":"Echterhof","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.chom.2026.06.013_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","article-title":"Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen","volume":"22","author":"Roach","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2026.06.013_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1681461","article-title":"Neutrophils, not macrophages, aid phage-mediated control of pulmonary Pseudomonas aeruginosa infection","volume":"16","author":"Weissfuss","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chom.2026.06.013_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102287","article-title":"Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy","volume":"24","author":"Bichet","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.chom.2026.06.013_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v15112211","article-title":"Human Complement Inhibits Myophages against Pseudomonas aeruginosa","volume":"15","author":"Egido","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/1751-7915.13414","article-title":"Bacteriophages engineered to display foreign peptides may become short-circulating phages","volume":"12","author":"Hodyra-Stefaniak","year":"2019","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.chom.2026.06.013_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33294-w","article-title":"Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler","volume":"13","author":"Van Nieuwenhuyse","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27656-z","article-title":"Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae","volume":"13","author":"Eskenazi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/aem.01269-25","article-title":"Mucofilm: a nexus for phage-microbiome interactions in gut ecology","volume":"91","author":"Mortensen","year":"2025","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib38","article-title":"Current Knowledge and Perspectives of Phage Therapy for Combating Refractory Wound Infections","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chom.2026.06.013_bib39","doi-asserted-by":"crossref","first-page":"e02573-17","DOI":"10.1128\/AAC.02573-17","article-title":"Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models","volume":"62","author":"Forti","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-52595-w","article-title":"Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs","volume":"15","author":"Kunisch","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib41","article-title":"Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-Resistant Acinetobacter baumannii","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ismejo\/wraf065","article-title":"Phage\u2013phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa","volume":"19","author":"B\u00fcrkle","year":"2025","journal-title":"ISME J."},{"key":"10.1016\/j.chom.2026.06.013_bib43","article-title":"Improving phage therapy by evasion of phage resistance mechanisms","volume":"6","author":"Bleriot","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"10.1016\/j.chom.2026.06.013_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","article-title":"Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial","volume":"24","author":"Kim","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00702-23","article-title":"Liver sinusoidal cells eliminate blood-borne phage K1F","volume":"9","author":"S\u00e1nchez Romano","year":"2024","journal-title":"mSphere"},{"key":"10.1016\/j.chom.2026.06.013_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/bact.1.4.17281","article-title":"Envisaging bacteria as phage targets","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"key":"10.1016\/j.chom.2026.06.013_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1292618","article-title":"A mechanism-based pathway toward administering highly active N-phage cocktails","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrmicro822","article-title":"Population and evolutionary dynamics of phage therapy","volume":"2","author":"Levin","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcsy.0000015","article-title":"Leveraging mathematical modeling framework to guide regimen strategy for phage therapy","volume":"1","author":"Yu","year":"2024","journal-title":"PLOS Complex Syst."},{"key":"10.1016\/j.chom.2026.06.013_bib50","article-title":"Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage PA_LZ7 in a mouse model","volume":"12","author":"Wang","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.chom.2026.06.013_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2180-11-195","article-title":"Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection","volume":"11","author":"Paul","year":"2011","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib52","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.12659\/MSM.917706","article-title":"Lytic Bacteriophage Screening Strategies for Multidrug-Resistant Bloodstream Infections in a Burn Intensive Care Unit","volume":"25","author":"Yang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.chom.2026.06.013_bib53","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.chom.2026.06.013_bib54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12275-011-1512-4","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"J. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110825","article-title":"Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy","volume":"39","author":"Delattre","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.chom.2026.06.013_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00614-23","article-title":"Interlaboratory comparison of Pseudomonas aeruginosa phage susceptibility testing","volume":"61","author":"Parmar","year":"2023","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.613529","article-title":"Analysis of Selection Methods to Develop Novel Phage Therapy Cocktails Against Antimicrobial Resistant Clinical Isolates of Bacteria","volume":"12","author":"Haines","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/21597081.2016.1220348","article-title":"Phage therapy dosing: The problem(s) with multiplicity of infection (MOI)","volume":"6","author":"Abedon","year":"2016","journal-title":"Bacteriophage"},{"key":"10.1016\/j.chom.2026.06.013_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14041","article-title":"Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans","volume":"25","author":"Haidar","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094690","article-title":"Phenotypic resistance and the dynamics of bacterial escape from phage control","volume":"9","author":"Bull","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.chom.2026.06.013_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002346","article-title":"The impact of phage and phage resistance on microbial community dynamics","volume":"22","author":"Alseth","year":"2024","journal-title":"PLOS Biol."},{"key":"10.1016\/j.chom.2026.06.013_bib62","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(21)00122-5","article-title":"The importance of understanding the infectious microenvironment","volume":"22","author":"Bjarnsholt","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj0341","article-title":"Accumulation of defense systems in phage-resistant strains of Pseudomonas aeruginosa","volume":"10","author":"Costa","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chom.2026.06.013_bib64","article-title":"Bacterial Receptors but Not Anti-Phage Defense Mechanisms Determine Host Range for a Pair of Pseudomonas aeruginosa Lytic Phages","author":"M\u00fcller","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.chom.2026.06.013_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tim.2019.10.007","article-title":"Steering Phages to Combat Bacterial Pathogens","volume":"28","author":"Gurney","year":"2020","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00037-23","article-title":"Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections","volume":"67","author":"Le","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chom.2026.06.013_bib67","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/ciaa705","article-title":"Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity","volume":"73","author":"Cano","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/v16071080","article-title":"Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia","volume":"16","author":"Teney","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clinthera.2023.06.009","article-title":"Phage Therapy for Diabetic Foot Infection: A Case Series","volume":"45","author":"Young","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.chom.2026.06.013_bib70","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/cid\/ciad335","article-title":"A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes","volume":"77","author":"Green","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107613","article-title":"Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection","volume":"66","author":"Cook","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.chom.2026.06.013_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf695.086","article-title":"234. Phage Therapy with BX211 Demonstrates Positive Efficacy Results in Staphylococcus Aureus Diabetic Foot Osteomyelitis: Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"13","author":"Lipsky","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF02932128","article-title":"Successful eradication of methicillin-resistantStaphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker \u2014 Case report","volume":"51","author":"Leszczy\u0144ski","year":"2006","journal-title":"Folia Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib74","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cid\/ciz782","article-title":"Eradication of a Multidrug-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Isolate Following Oral and Intra-rectal Therapy With a Custom Made, Lytic Bacteriophage Preparation","volume":"70","author":"Corbellino","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.chom.2026.06.013_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082474","article-title":"PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults","volume":"12","author":"Grubb","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.chom.2026.06.013_bib76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.chom.2026.06.013_bib77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2013.05.022","article-title":"Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects","volume":"443","author":"McCallin","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.chom.2026.06.013_bib78","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0121-2022","article-title":"Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations","volume":"31","author":"Mitropoulou","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.chom.2026.06.013_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00408-024-00700-7","article-title":"Phage Therapy for Respiratory Infections: Opportunities and Challenges","volume":"202","author":"Khosravi","year":"2024","journal-title":"Lung"},{"key":"10.1016\/j.chom.2026.06.013_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/v13101901","article-title":"Phage Therapy Experience at the Eliava Phage Therapy Center: Three Cases of Bacterial Persistence","volume":"13","author":"Zaldastanishvili","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5582\/bst.2022.01147","article-title":"Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"16","author":"Chen","year":"2022","journal-title":"BioSci. Trends"},{"key":"10.1016\/j.chom.2026.06.013_bib83","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14787210.2019.1646126","article-title":"Factors determining phage stability\/activity: challenges in practical phage application","volume":"17","author":"Jo\u0144czyk-Matysiak","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.chom.2026.06.013_bib84","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad406","article-title":"Rapid assessment of changes in phage bioactivity using dynamic light scattering","volume":"2","author":"Dharmaraj","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.chom.2026.06.013_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/v13050865","article-title":"Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium","volume":"13","author":"Duyvejonck","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01442-24","article-title":"Comparative evaluation of long-term preservation methods for morphologically distinct bacteriophages","volume":"13","author":"Huang","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.chom.2026.06.013_bib87","doi-asserted-by":"crossref","DOI":"10.1128\/aem.01545-22","article-title":"Viral Preservation with Protein-Supplemented Nebulizing Media in Aerosols","volume":"89","author":"Humphrey","year":"2023","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib88","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01673-5","article-title":"The Stabilizing Excipients in Dry State Therapeutic Phage Formulations","volume":"21","author":"Zhang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.chom.2026.06.013_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/v16071155","article-title":"Development of Stabilizing Solution for Long-Term Storage of Bacteriophages at Room Temperature and Application to Control Foodborne Pathogens","volume":"16","author":"Kim","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib90","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","article-title":"Standardized bacteriophage purification for personalized phage therapy","volume":"15","author":"Luong","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.chom.2026.06.013_bib91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000315915","article-title":"Endotoxins and other sepsis triggers","volume":"167","author":"Opal","year":"2010","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.chom.2026.06.013_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-64608-3","article-title":"Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance","volume":"16","author":"Moon","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib93","doi-asserted-by":"crossref","first-page":"e01979-20","DOI":"10.1128\/AEM.01979-20","article-title":"Encapsulation and Delivery of Therapeutic Phages","volume":"87","author":"Loh","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2019.01.050","article-title":"Storage stability of inhalable phage powders containing lactose at ambient conditions","volume":"560","author":"Chang","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.chom.2026.06.013_bib95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation\u2014A proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.chom.2026.06.013_bib96","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rmed.2007.11.003","article-title":"Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD","volume":"102","author":"Lavorini","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.chom.2026.06.013_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090475","article-title":"Microencapsulation of Enteric Bacteriophages in a pH-Responsive Solid Oral Dosage Formulation Using a Scalable Membrane Emulsification Process","volume":"11","author":"Vinner","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chom.2026.06.013_bib98","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jconrel.2022.11.048","article-title":"Encapsulation and delivery of phage as a novel method for gut flora manipulation in situ: A review","volume":"353","author":"Yang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chom.2026.06.013_bib99","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1021\/acsabm.5c00933","article-title":"Application of Phage-Modified Conjugated Polymer-Based Nanoparticles in the Disruption of Bacterial Biofilms","volume":"8","author":"Cai","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.chom.2026.06.013_bib100","doi-asserted-by":"crossref","first-page":"26928","DOI":"10.1021\/acsnano.4c08671","article-title":"Engineered Bacteriophage-Polymer Nanoassemblies for Treatment of Wound Biofilm Infections","volume":"18","author":"Park","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.chom.2026.06.013_bib101","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/btpr.1898","article-title":"Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions","volume":"30","author":"Esteban","year":"2014","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.chom.2026.06.013_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijfoodmicro.2025.111470","article-title":"Bacteriophage emulsion for prevention of Salmonella contamination in eggshells","volume":"445","author":"Jo","year":"2026","journal-title":"Int. J. Food Microbiol."},{"key":"10.1016\/j.chom.2026.06.013_bib103","article-title":"Dosing and Delivery of Bacteriophage Therapy In a Murine Wound Infection Model","author":"Lin","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.chom.2026.06.013_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202509360","article-title":"Bio-Responsive Hydrogel for Targeted on-Demand Release of a Phage Cocktail for Treatment of Pseudomonas aeruginosa Infection","volume":"36","author":"Tao","year":"2026","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.chom.2026.06.013_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.134484","article-title":"Evaluation of MDR-specific phage P\u0278-Mi-Pa loaded mucoadhesive electrospun nanofibrous scaffolds against drug-resistant Pseudomonas aeruginosa- induced wound infections in an animal model","volume":"277","author":"Ilomuanya","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.chom.2026.06.013_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81580-2","article-title":"Designing P. aeruginosa synthetic phages with reduced genomes","volume":"11","author":"Pires","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2026.06.013_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101257","article-title":"Safety, recovery, and pharmacodynamics of CRISPR\u2013Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study","volume":"7","author":"Petersen","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.chom.2026.06.013_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17101288","article-title":"Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms","volume":"17","author":"Aldhubiab","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.chom.2026.06.013_bib109","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acs.chemrev.4c00681","article-title":"Engineering Phages to Fight Multidrug-Resistant Bacteria","volume":"125","author":"Peng","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.chom.2026.06.013_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2005.05.014","article-title":"An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold","volume":"114","author":"Vitiello","year":"2005","journal-title":"Virus Res."},{"key":"10.1016\/j.chom.2026.06.013_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/v16040570","article-title":"Improving Pharmacokinetics of Peptides Using Phage Display","volume":"16","author":"Asar","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.chom.2026.06.013_bib112","doi-asserted-by":"crossref","DOI":"10.4014\/jmb.2509.09050","article-title":"PEGylation Overcomes Pharmacological Barriers to Improve Systemic Pharmacokinetics and Therapeutic Efficacy of Phages against MDR Escherichia coli","volume":"35","author":"Shamsuzzaman","year":"2025","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.chom.2026.06.013_bib113","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ac4aa7","article-title":"Controlled release of metal phenolic network protected phage for treating bacterial infection","volume":"33","author":"Sun","year":"2022","journal-title":"Nanotechnology"},{"key":"10.1016\/j.chom.2026.06.013_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19124-x","article-title":"Exploring the synthetic biology potential of bacteriophages for engineering non-model bacteria","volume":"11","author":"Lammens","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.06.013_bib115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40259-021-00480-z","article-title":"Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future","volume":"35","author":"\u0141obocka","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.chom.2026.06.013_bib116","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.medmal.2008.06.023","article-title":"Phage therapy experience at the Eliava Institute","volume":"38","author":"Kutateladze","year":"2008","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.chom.2026.06.013_bib117","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/cid\/ciad481","article-title":"Magistral Phage Preparations: Is This the Model for Everyone?","volume":"77","author":"Pirnay","year":"2023","journal-title":"Clin. Infect. Dis."}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826002738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826002738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:08:28Z","timestamp":1784088508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312826002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":117,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1931312826002738"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2026.06.013","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking down barriers to improve phage therapy delivery","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}